Literature DB >> 18580870

Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.

R Krishna1, A J Bergman, B Jin, M Fallon, J Cote, P Van Hoydonck, T Laethem, I N Gendrano, K Van Dyck, D Hilliard, O Laterza, K Snyder, C Chavez-Eng, R Lutz, J Chen, D M Bloomfield, M De Smet, L M Van Bortel, M Gutierrez, N Al-Huniti, K Dykstra, K M Gottesdiener, J A Wagner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18580870     DOI： 10.1038/clpt.2008.109

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  25 in total

1.  Biochemical characterization of cholesteryl ester transfer protein inhibitors.

Authors:  Mollie Ranalletta; Kathleen K Bierilo; Ying Chen; Denise Milot; Qing Chen; Elaine Tung; Caroline Houde; Nadine H Elowe; Margarita Garcia-Calvo; Gene Porter; Suzanne Eveland; Betsy Frantz-Wattley; Mike Kavana; George Addona; Peter Sinclair; Carl Sparrow; Edward A O'Neill; Ken S Koblan; Ayesha Sitlani; Brian Hubbard; Timothy S Fisher
Journal:  J Lipid Res       Date:  2010-05-10       Impact factor: 5.922

2.  Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.

Authors:  Amir Hooshang Mohammadpour; Fatemeh Akhlaghi
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

3.  Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor.

Authors:  Rajesh Krishna; Arthur J Bergman; Michele Green; Marissa F Dockendorf; John A Wagner; Kevin Dykstra
Journal:  AAPS J       Date:  2011-02-23       Impact factor: 4.009

4.  Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Authors:  Rajesh Krishna; Daria Stypinski; Melissa Ali; Amit Garg; Josee Cote; Andrea Maes; Bruce Degroot; Yang Liu; Susie Li; Sandra M Connolly; John A Wagner; S Aubrey Stoch
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

Review 5.  New horizons for cholesterol ester transfer protein inhibitors.

Authors:  Gregory G Schwartz
Journal:  Curr Atheroscler Rep       Date:  2012-02       Impact factor: 5.113

6.  Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.

Authors:  Gissette Reyes-Soffer; John S Millar; Colleen Ngai; Patricia Jumes; Ellie Coromilas; Bela Asztalos; Amy O Johnson-Levonas; John A Wagner; Daniel S Donovan; Wahida Karmally; Rajasekhar Ramakrishnan; Stephen Holleran; Tiffany Thomas; Richard L Dunbar; Emil M deGoma; Hashmi Rafeek; Amanda L Baer; Yang Liu; Michael E Lassman; David E Gutstein; Daniel J Rader; Henry N Ginsberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-03-10       Impact factor: 8.311

Review 7.  Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.

Authors:  Richard Kones
Journal:  Drug Des Devel Ther       Date:  2011-06-13       Impact factor: 4.162

Review 8.  The hypertension peril: lessons from CETP inhibitors.

Authors:  Matthias Hermann; Frank T Ruschitzka
Journal:  Curr Hypertens Rep       Date:  2009-02       Impact factor: 5.369

9.  Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.

Authors:  Eric J Niesor; Christine Magg; Naoto Ogawa; Hiroshi Okamoto; Elisabeth von der Mark; Hugues Matile; Georg Schmid; Roger G Clerc; Evelyne Chaput; Denise Blum-Kaelin; Walter Huber; Ralf Thoma; Philippe Pflieger; Makoto Kakutani; Daisuke Takahashi; Gregor Dernick; Cyrille Maugeais
Journal:  J Lipid Res       Date:  2010-09-22       Impact factor: 5.922

10.  Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.

Authors:  Rajesh Krishna; Amit Garg; Deborah Panebianco; Josee Cote; Arthur J Bergman; Pascale Van Hoydonck; Tine Laethem; Kristien Van Dyck; Jingjing Chen; Cynthia Chavez-Eng; Laura Archer; Ryan Lutz; Deborah Hilliard; Karen Snyder; Bo Jin; Luc Van Bortel; Kenneth C Lasseter; Nidal Al-Huniti; Kevin Dykstra; Keith Gottesdiener; John A Wagner
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.